Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
15.81
-0.16 (-1.00%)
At close: Mar 2, 2026, 4:00 PM EST
15.10
-0.71 (-4.49%)
Pre-market: Mar 3, 2026, 5:37 AM EST
Nurix Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Nurix Therapeutics stock have an average target of 29.46, with a low estimate of 16 and a high estimate of 36. The average target predicts an increase of 86.34% from the current stock price of 15.81.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 29, 2026.
Analyst Ratings
The average analyst rating for Nurix Therapeutics stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Buy | 7 | 6 | 5 | 7 | 7 | 6 |
| Hold | 2 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 13 | 14 | 14 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $32 → $35 | Buy | Maintains | $32 → $35 | +121.38% | Jan 29, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $28 → $30 | Buy | Maintains | $28 → $30 | +89.75% | Jan 29, 2026 |
| Stifel | Stifel | Strong Buy Maintains $33 → $35 | Strong Buy | Maintains | $33 → $35 | +121.38% | Jan 29, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $30 → $29 | Buy | Maintains | $30 → $29 | +83.43% | Jan 29, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +89.75% | Jan 29, 2026 |
Financial Forecast
Revenue This Year
63.73M
from 83.98M
Decreased by -24.11%
Revenue Next Year
80.51M
from 63.73M
Increased by 26.32%
EPS This Year
-3.11
from -3.05
EPS Next Year
-2.99
from -3.11
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 99.8M | 233.7M | |||
| Avg | 63.7M | 80.5M | |||
| Low | 49.0M | 49.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 18.8% | 266.7% | |||
| Avg | -24.1% | 26.3% | |||
| Low | -41.7% | -23.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.69 | -2.17 | |||
| Avg | -3.11 | -2.99 | |||
| Low | -3.64 | -3.34 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.